TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05496998: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR Transfemoral System in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

Sponsor: Medtronic Cardiovascular · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 400 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,706,400

Rescue Site Savings

+$4,415,600

Unlock Full NCT05496998 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05496998 Rescue Dossier →